

Nishio, M., Yamanaka, T., Matsumoto, K., Kimura, H., Sakai, K., Sakai, A., Sone, T., Horiike, A., Koizumi, F., Kasahara, K., Ohira, T., Ikeda, N., Saijo, N., Arao, T., Nishio K.	Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.	J Thorac Oncol	6(11)	1889-94	2011
Fujita, Y., Islam, R., Kaneda, H., Kudo, K., Tamura, D., Aomatsu, K., Nagai, T., Kimura, H., Matsutmoto, K., Velasco, MA., Arao, T., Okawara, T., Nishio K.	Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.	Invest New Drugs	E-pub ahead of print		2011
Goto, K., Ichinose, Y., Ohe, Y., Yamamoto, N., Negoro, S., Nishio K., Itoh, Y., Jiang, H., Duffield, E., McCormack, R., Saijo, N., Mok, T, Fukuoka, M.	Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.	J Thorac Oncol	7(1)	115-21	2012
Yonesaka, K., Zejmullahu, K., Okamoto, I., Satoh, T., Cappuzzo, F., Souglakos, J., Ercan, D., Rogers, A., Roncalli, M., Takeda, M., Fujisaka, Y., Philips, J., Shimizu, T., Maenishi, O, Cho, Y., Sun, J., Destro, A., Taira, K., Takeda, K., Okabe, T., Swanson, J., Shivdasani, RA., Nishio K., et al	Activation of ERBB2 signaling causes resistance to the EGFR-derected therapeutic antibody cetuximab.	Sci Transl Med	3(99)	99ra86	2011
Wakai T, Korita P V, Ajioka Y, Inoue M, Takamura M, Akazawa K, shirai Y, Hatakeyama K	Intraepithelial Ductal Spread in Colorectal Carcinoma Liver Metastasis.	Hepato-Gastroenterology	58	583-588	2011
Okusaka T, Furuse J.	Session 3: Hepatocellular carcinoma. Chemotherapy and recent clinical trials for HCC in Japan.	2 nd Japan-Taiwan Joint symposium on Medical Oncology (Dec12-13, 2009). Journal of the Chinese Oncology Society (JCOS)	1	30-35	2011

Okusaka T, Kasugai H, Ishii H, <u>Kudo M</u> , Sata M, Tanaka K, Shioyama Y, Chayama K, Kumada H, Yoshikawa M, Seki T, Saito H, Hayashi N, Shiratori K, Okita K, <u>Sakaida I</u> , Honda M, Kusumoto Y, Tsutsumi T, Sakata K.	A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma.	Invest New Drug, [Epub ahead of print],		in press.	2011
Kanai F, Yoshida H, Tateishi R, Sato S, Kawabe T, <u>Obi S</u> , Kondo Y, Taniguchi M, Tagawa K, <u>Ikeda M</u> , Morizane C, Okusaka T, Arioka H, Shiina S, Omata M.	A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma.	Cancer Chemother Pharmacol	67 (2)	315-324.	2011
Totoki Y, Tatsuno K, Yamamoto S, <u>Arai Y</u> , Hosoda F, Ishikawa S, Tsutsumi S, Totsuka H, Shirakihara T, Sakamoto S, Ojima H, Shimada K, Kosuge T, <u>Okusaka T</u> , Kato K, Kusuda J, Yoshida T, Aburatani H, Shibata T.	High-resolution characterization of a hepatocellular carcinoma genome.	Nat Genet	43 (5)	464-469.	2011
Suzuki E, Furuse J, <u>Ikeda M</u> , Ishii H, <u>Okusaka T</u> , Nakachi K, Mitsunaga S, Ueno H, Morizane C.	A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.	Jpn J Clin Oncol	41 (3)	328-333.	2011
Toyoda H, <u>Kumada T</u>	Incidence of HCC and response to IFN therapy in HCV-infected patients: effect of factors associated with the therapeutic response and incidence of HCC.	Liver Int	in press		2012
Toyoda H, <u>Kumada T</u> , Tada T, Sone Y, Fujimori M.	Transarterial chemoembolization for hepatitis B virus-associated hepatocellular carcinoma: improved survival following concomitant treatment with nucleoside analogues.	J Vasc Intervent Radiol	in press		2012
Toyoda H, <u>Kumada T</u> , Tada T	Highly sensitive Lens culinaris agglutinin-reactive alpha-fetoprotein (hs-AFP-L3): a new tool for the management of hepatocellular carcinoma.	Oncology	81	S61-S65.	2011
Matsushima-Nishiwaki R, Adachi S, Yoshioka T, Yasuda E, Yamagishi Y, Matsuura J, Muko M, Iwamura R, Noda T, Toyoda H, Kaneoka Y, Okano Y, <u>Kumada T</u> , Kozawa O.	Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen-activated protein kinases and AKT pathways.	J Cell Biochem	112	3430-3439	2011

Toyoda H, <u>Kumada T</u> , Tada T, Sone Y, Kaneoka Y, Maeda A.	Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan.	Gastroenterol Hepatol 2011	26	1765-1771	2011
Toyoda H, <u>Kumada T</u> , Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S.	Clinical utility of high sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein level less than 20 ng/mL.	Cancer Sci	102	1025-1031	2011
oyoda H, <u>Kumada T</u> , Kaneoka Y, Maeda A.	Amino acid substitutions in the hepatitis C virus core region are associated with post-operative recurrence and survival of patients with HCV genotype 1b-associated hepatocellular carcinoma.	Ann Surg	254	326-332	2011
<u>Kumada T</u> , Toyoda H, Arakawa T, Sone Y, Fujimori M, Ogawa S, Ishikawa T	Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase using Gd-EOB-DTPA enhanced magnetic resonance imaging.	Am J Roentgenol	197	58-63	2011
<u>Kumada T</u> , Toyoda H, Kiriyaama S, Tanikawa M, Hisanaga Y, Kanamoti A, Tada T, Tanaka J, Yoshizawa H.	Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus	J Gastroenterol	46	536-544	2011
Okusaka T, Ueno H, <u>Ikeda M</u> , Morizane C.	Phase I and pharmacokinetic clinical trial of oral administration of the acyclic retinoid NIK-333.	Hepatol Res.	41(6)	542-52	2011
Kawashima M, Kohno R, Nakachi K, Nishio T, Mitsunaga S, <u>Ikeda M</u> , Konishi M, Takahashi S, Gotohda N, Arahira S, Zenda S, Ogino T, Kinoshita T.	Dose-Volume Histogram Analysis of the Safety of Proton Beam Therapy for Unresectable Hepatocellular Carcinoma.	Int J Radiat Oncol Biol Phys.	79(5)	1479-86	2011
Iwasa S, <u>Ikeda M</u> , <u>Arai Y</u> . et al.	Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.	Jpn J Clin Oncol.	41(6)	770-5	2011
Tomimaru Y et. al	Advantage of autologous blood transfusion in surgery for hepatocellular carcinoma.	World J Gastroenterol.	17(32)	3709-15	2011
Tomokuni A et. al	miR-146a suppresses the sensitivity to interferon- α in hepatocellular carcinoma cells.	Biochem Biophys Res Commun.	414(4)	675-80	2011

Nagano H et. al	Long-term outcome of combined interferon- α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis.	Oncology.	80(1-2)	63-9	2011
Kobayashi S et. al	Experience with the use of fibrin sealant plus polyglycolic acid felt at the cut surface of the liver in laparoscopic hepatectomy.	Surg Endosc.	25(11)	3590-6	2011
Tomimaru Y et. al	IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma.	Int J Cancer.	130(2)	319-27	2012
Marubashi S et. al	Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma.	Ann Surg Oncol.	18(8)	2200-9	2011
Noda T et. al	Prognosis of hepatocellular carcinoma with biliary tumor thrombi after liver surgery.	.Surgery	149(3)	371-7	2011
Murakami M et. al	Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon- α /5-fluorouracil therapy for hepatocellular carcinoma cells.	Ann Surg Oncol.	18(2)	589-96	2011
Noda T et. al	PLOD2 induced under hypoxia is a novel prognostic factor for hepatocellular carcinoma after curative resection.	Liver Int.	32(1)	110-8.	2012
Tomimaru Y et. al	Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma.	J Hepatol.	56(1)	167-75	2012
Yamada D et. al	Role of the Hypoxia-Related Gene, JMJD1A, in Hepatocellular Carcinoma Clinical Impact on Recurrence after Hepatic Resection.	Ann Surg Oncol.	in press	in press	in press
Kim C et. al	Significance of Alanine Aminopeptidase N (APN) in Bile in the Diagnosis of Acute Cellular Rejection After Liver Transplantation.	J Surg Res.	in press	in press	in press
Sato F, Hatano E, Koji Kitamura, Myomoto A, Fujiwara T, Takizawa S, Tsuchiya S, Tsujimoto G, Uemoto S, Shimizu K	MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria.	PLoS One	6(1)	e16435	2011

Kitamura K, <u>Hatano E</u> , Higashi T, Seo S, Nakamoto Y, Yamanaka K, Iida T, Taura K, Yasuchika K, Uemoto S	Preoperative FDG-PET Predicts Recurrence Patterns in Hepatocellular Carcinoma.	Ann Surg Oncol	19(1)	156-162	2012
Arizono S, Isoda H, <u>Hatano E</u> , Togashi K	Uptake of gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid in metastatic adrenal tumour from hepatocellular carcinoma.	Br J Radiol	84(1005)	e182-5	2011
Yamanaka K, <u>Hatano E</u> , Kitamura K, Kida T, Ishii T, Machimoto T, Taura K, Yasuchika K, Isoda H, Shibata T, Uemoto S	Early evaluation of transcatheter chemoembolization-refractory hepatocellular carcinoma	J Gastroenterology	Epub ahead of print		
Tateyama M, Yatsuhashi H, Taura N, Motoyoshi Y, Nagaoka S, Yanagi K, Abiru S, Komori A, Migita K, Nakamura M, Nagahama K, <u>Sasaki Y</u> , Miyakawa Y and Ishibashi H.	Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.	J Gastroenterol	46	92-100	2011
Taura N, Fukushima N, Yatsuhashi H, Takami Y, Seike M, Watanabe H, Mizuta T, <u>Sasaki Y</u> , Ngata K, et al	The incidence of hepatocellular associated with hepatitis C infection decreased in Kyushu area	Med Sci Monit		7-11	2011
Watanabe T, Ishihara K, Hirose A, Watanabe S, Hino S, Ojima H, Kanai Y, <u>Sasaki Y</u> , Nakao M,	Higher-Order Chromatin Regulation and Differential Gene Expression in the Human Tumor Necrosis Factor/Lymphotoxin Locus in Hepatocellular Carcinoma Cells	Mol Cell Biol			in press
Murakami E, <u>Aikata H</u> , Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Kimura T, Kenjo M, Nagata Y, Ishikawa M, Kakizawa H, Awai K, Chayama K	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava	Hepatol Res.			2011
Nagaoki Y, Hyogo H, <u>Aikata H</u> , Tanaka M, Naeshiro N, Nakahara T, Honda Y, et al	Recent trend of clinical features in patients with hepatocellular carcinoma.	Hepatol Res.			2011
Kodama H, <u>Aikata H</u> , Murakami E, Miyaki D, Nagaoki Y, Hashimoto Y, Azakami T, Katamura Y, Kawaoka T, et al	Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus.	Hepatol Res.	41	1046-56	2011

Kawaoka T, Aikata H, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Tashiro H, Ohdan H, Chayama K.	IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.	J Viral Hepat.	18	550-60	2011
Miki D, Ochi H, Hayes CN, Abe H, Yoshima T, Aikata H, Ikeda K, Kumada H, Toyota J, Morizono T, Tsunoda T, Kubo M, Nakamura Y, Kamatani N, Chayama K.	Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers.	Nat Genet.	43	797-800	2011
Tanimoto Y, Tashiro H, Aikata H, Amano H, Oshita A, Kobayashi T, Kuroda S, Tazawa H, Takahashi S, Itamoto T, Chayama K, Ohdan H.	Impact of pegylated interferon therapy on outcomes of patients with hepatitis C virus-related hepatocellular carcinoma after curative hepatic resection.	Ann Surg Oncol.	19	418-25	2011
Tashiro H, Aikata H, Waki K, Amano H, Oshita A, Kobayashi T, Tanimoto Y, Kuroda S, Tazawa H, Chayama K, Asahara T, Ohdan H.	Treatment strategy for early hepatocellular carcinomas: comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection.	J Surg Oncol.	104	3-9	2011
Nagaoki Y, Aikata H, Miyaki D, Murakami E, Hashimoto Y, Katamura Y, Azakami T, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Chayama K.	Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy.	J Gastroenterol.	46	799-808	2011
Yamasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, Terai S, Sakaida I	A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial.	J Gastroenterol	Mar;46(3)	359-66	2011
Yamasaki T, Terai S, Sakaida I	Deferoxamine for advanced hepatocellular carcinoma.	N Engl J Med	365(6)	576-8	2011
Yamasaki T, Sakaida I	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders.	Hepatol Res	Epub ahead of print		
Fujisawa K, Terai S, Hirose Y, Takami T, Yamamoto N, Sakaida I	Senescence marker protein 30 (SMP30)/regucalcin (RGN) expression decreases with aging, acute liver injuries and tumors in zebrafish.	Biochem Biophys Res Commun	414(2)	331-6	2011
Iizuka N, Oka M, Sakaida I, Moribe T, Miura T, Kimura N, Tamatsukuri S, et al	Efficient detection of hepatocellular carcinoma by a hybrid blood test of epigenetic and classical protein markers.	Clin Chim Acta	412(1-2)	152-8	2011

Enooku K, Tateishi R, <u>Kanai F</u> , Kondo Y, Masuzaki R, Goto T, Shiina S, Yoshida H, Omata M, Koike K	Evaluation of molecular targeted cancer drug by changes in tumor marker doubling times.	J Gastroenterol	47(1)	71-8	2012
Chiba T, Suzuki E, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, <u>Kanai F</u> , Imazeki F, Iwama A, Yokosuka O	3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells.	Int J Cancer		Epub ahead of print	
Kudo Y, Tanaka Y, Tateishi K, <u>Yamamoto K</u> , Yamamoto S, Mohri D, Isomura Y, Seto M, Nakagawa H, Asaoka Y, Tada M, Ohta M, Ijichi H, Hirata Y, Otsuka M, Ikenoue T, Maeda S, Shiina S, Yoshida H, Nakajima O, <u>Kanai F</u> , Omata M, Koike K	Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway.	J Hepatol	55(6)	1400-8	2011
Ogasawara, <u>Kanai F</u> , Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, et al	Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.	Hepatology International	5(3)	850-6	2011
Kurosaki M, <u>Izumi N</u> , et al.	Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.	J Hepatol	In press		2012
Watanabe S, <u>Izumi N</u> et al.	Cancer preventive effect of pegylated interferon α -2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis.	Hepatol Res	41	955-64	2011
Kurosaki M, <u>Izumi N</u> , et al.	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy.	Hepatol Res	40	870-7	2010
Asahina Y, <u>Izumi N</u> , et al.	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.	Hepatology	52	518-27	2010
Tschiya K, <u>Izumi N</u> et al.	Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation.	Oncology	80	278-88	2011

Kuzuya T, <u>Izumi N</u> et al.	Early decrease in α -fetoprotein but not des- γ -carboxy prothrombin predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.	Oncology	81	251-8	2011
Kawaguchi T, <u>Izumi N</u> et al.	Branched-chain amino acids as pharmacological nutrients in chronic liver disease.	Hepatology	54	1063-70	2011
<u>Izumi N</u>	Prediction and prevention of intrahepatic recurrence of hepatocellular carcinoma.	Hepatology Res	In press		2012
<u>Izumi N</u>	Recent advances of radiofrequency ablation for early hepatocellular carcinoma	J Gastroenterol Hepatol	26	115-22	2011
Hiroki Nishikawa, Tadashi Inuzuka, Haruhiko Takeda, Jun Nakajima, Azusa Sakamoto, Sinichiro Henmi, Tetsuro Ishikawa, Sumio Saito, Ryuichi Kita, Toru Kimura, Yukio <u>Osaki</u> , Yorimitsu Koshikawa	A Case of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Refractory to Epirubicin That Showed Marked Decrease in Tumor Markers after Transcatheter Arterial Infusion with Miriplatin.	Case Reports in Oncology	4	327-335	2011
Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T, <u>Osaki Y</u>	Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation.	Journal of Gastroenterology	46	1418-1426	2011
Nishikawa H, Inuzuka T, Takeda H, Nakajima J, Sakamoto A, Henmi S, Matsuda F, Eso Y, Ishikawa T, Saito S, Kita R, Kimura T, <u>Osaki Y</u>	Comparison of percutaneous radiofrequency thermal ablation and surgical resection for small hepatocellular carcinoma.	BMG gastroenterology	11	143	2011
Tadashi Inuzuka, Hiroki Nishikawa, Akira Sekikawa, Haruhiko Takeda, Shinichiro Henmi, Azusa Sakamoto, Sumio Saito, Ryuichi Kita, Toru Kimura, <u>Yukio Osaki</u> , <u>Msatoshi Kudo</u>	Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report.	Oncology	81	152-157	2011
<u>Osaki Y</u> , Ueda Y, Marusawa H, Nakajima J, Kimura T, Kita R, Nishikawa H, Saito S, Henmi S, Sakamoto A, Eso Y, Chiba T	Decrease in alpha-fetoprotein levels predicts reduced incidence of hepatocellular carcinoma in patients with hepatitis C virus infection receiving interferon therapy: a single center study.	Journal of Gastroenterology	Epub ahead of print		

Kinugasa H, <u>Yamamoto K</u> et al.	Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma.	J Gastroenterol.	Nov3		2011
Miyahara K, <u>Yamamoto K</u> , et al.	Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.	J Gastroenterol Hepatol.	26(11)	1604-11.	2011
Nouso K, <u>Yamamoto K</u> et al.	Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein.	J Gastroenterol Hepatol.	26(7)	1195-200	2011
Kobashi H, <u>Yamamoto K</u> et al.	Long-term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine.	Hepatol Res.	41(5)	405-16	2011
Tomoda T, <u>Yamamoto K</u> et al.	Genetic risk of hepatocellular carcinoma in patients with hepatitis C virus: a case control study.	J Gastroenterol Hepatol.	<u>Yamamoto K</u>		2011
Nakanishi Y, <u>Yamamoto K</u> et al.	Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis.	BMC Cancer.	11(1)	3	2011
Miyatake H, <u>Yamamoto K</u> et al.	Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-Related Hepatocellular Carcinoma.	Dig Dis Sci.	Oct 12		2011
Kinugasa H, <u>Yamamoto K</u> et al.	Hepatocellular carcinoma occurring in hepatobiliary fibropolycystic disease.	Hepatol Res.	41(3)	277-81	2011
Kuwaki K, <u>Yamamoto K</u> et al.	Prognostic model for hepatocellular carcinoma with time-dependent factors.	Acta Med Okayama.	65(1)	11-9	2011
Hagihara H, <u>Yamamoto K</u> et al.	Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma.	Int J Clin Oncol.	16(3)	210-20	2011
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arai S, <u>Imai Y</u> , Shima T, Kanbara Y, Saibara T, Mori T, et al	Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma	Clin Gastroenterol Hepatol	9	428-433	2011

Murakami T, <u>Imai Y</u> , Okada M, Hyodo T, Lee WJ, Kim MJ, Kim T, Choi BI	US, CT and MR imaging of hepatocellular carcinoma: Toward improved treatment decisions	Oncology	81	Suppl 1:86-99.	2011
Yasui K, Hashimoto E, Komorizono Y, Koike K, Arai S, <u>Imai Y</u> , et al	Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma	Clin Gastroenterol and Hepatol	9	428-433	2011
Katsube T, Okada M, Kumano S, Imaoka I, Kagawa Y, Hori M, Ishii K, Tanigawa N, <u>Imai Y</u> , Kudo M, Murakami T	Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging.	Eur J Radiol			2011 Apr 20. [Epub ahead of print]
Onishi H, Kim T, <u>Imai Y</u> , Hori M, <u>Nagano H</u> , Nakaya Y, Tsuboyama T, Nakamoto A, Tatsumi M, Kumano S, Okada M, Takamura M, Wakasa K, Tomiyama N, Murakami T	Hypervascular hepatocellular carcinomas: Detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT.	Eur Radiol			2011 Nov 7. [Epub ahead of print]
Tomiyama Y, Yoshioka N, Yanai Y, Kawase T, Nishina S, Hara Y, Yoshida K, Korenaga K, Korenaga M, <u>Hino K</u> .	Type 1 interferon receptor in peripheral blood mononuclear cells may predict response to intra-arterial 5-fluorouracil + interferon therapy for advanced hepatocellular carcinoma	Hepatic Medicine : Evidence and Research	3	45-52	2011
Doi N, Tomiyama Y, Kawase T, Nishina S, Yoshioka N, Hara Y, Yoshida K, Korenaga K, Korenaga M, Moriya T, Urakami A, Nakashima O, Kojiro M, <u>Hino K</u>	Focal nodular hyperplasia-like nodule with reduced expression of organic anion transporter 1B3 in alcoholic liver cirrhosis.	Intern Med	50	1193-9	2011

IV. 研究成果の刊行物・別刷

Molecular Cancer Therapeutics



Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

Tomoyuki Nagai, Tokuzo Arao, Kazuyuki Furuta, et al.

Mol Cancer Ther 2011;10:169-177. Published online January 10, 2011.

Updated Version	Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-10-0544
Supplementary Material	Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2011/01/10/10.1.169.DC1.html

Cited Articles	This article cites 33 articles, 13 of which you can access for free at: http://mct.aacrjournals.org/content/10/1/169.full.html#ref-list-1
-----------------------	--

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .

Sorafenib Inhibits the Hepatocyte Growth Factor–Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma

Tomoyuki Nagai^{1,2}, Tokuzo Arao¹, Kazuyuki Furuta¹, Kazuko Sakai¹, Kanae Kudo^{1,2}, Hiroyasu Kaneda¹, Daisuke Tamura¹, Keiichi Aomatsu¹, Hideharu Kimura¹, Yoshihiko Fujita¹, Kazuko Matsumoto¹, Nagahiro Saijo³, Masatoshi Kudo², and Kazuto Nishio¹

Abstract

The epithelial mesenchymal transition (EMT) has emerged as a pivotal event in the development of the invasive and metastatic potentials of cancer progression. Sorafenib, a VEGFR inhibitor with activity against RAF kinase, is active against hepatocellular carcinoma (HCC); however, the possible involvement of sorafenib in the EMT remains unclear. Here, we examined the effect of sorafenib on the EMT. Hepatocyte growth factor (HGF) induced EMT-like morphologic changes and the upregulation of SNAI1 and N-cadherin expression. The downregulation of E-cadherin expression in HepG2 and Huh7 HCC cell lines shows that HGF mediates the EMT in HCC. The knockdown of SNAI1 using siRNA canceled the HGF-mediated morphologic changes and cadherin switching, indicating that SNAI1 is required for the HGF-mediated EMT in HCC. Interestingly, sorafenib and the MEK inhibitor U0126 markedly inhibited the HGF-induced morphologic changes, SNAI1 upregulation, and cadherin switching, whereas the PI3 kinase inhibitor wortmannin did not. Collectively, these findings indicate that sorafenib downregulates SNAI1 expression by inhibiting mitogen-activated protein kinase (MAPK) signaling, thereby inhibiting the EMT in HCC cells. In fact, a wound healing and migration assay revealed that sorafenib completely canceled the HGF-mediated cellular migration in HCC cells. In conclusion, we found that sorafenib exerts a potent inhibitory activity against the EMT by inhibiting MAPK signaling and SNAI1 expression in HCC. Our findings may provide a novel insight into the anti-EMT effect of tyrosine kinase inhibitors in cancer cells. *Mol Cancer Ther*; 10(1); 169–77. ©2011 AACR.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third largest cause of cancer-related death in the world annually (1). Recurrence, metastasis, and the development of new primary tumors are the most common causes of mortality among patients with HCC (2). Sorafenib (Nexavar; Bayer HealthCare Pharmaceuticals Inc.) is a small molecule that inhibits the kinase activities of Raf-1 and B-Raf in addition to VEGFRs, PDGFR- β (platelet-derived growth factor receptor β), Flt-3, and c-KIT (3). Two recent randomized controlled trials reported a clinical benefit of single-agent sorafenib in extending overall survival in both Western and Asian patients with advanced unresectable HCC (4, 5). The

potential action mechanisms that lead to these clinical benefits are thought to include antiangiogenic effects and sorafenib's characteristic inhibitory effect on Raf-1 and B-Raf signaling.

Meanwhile, growing evidence indicates that the epithelial mesenchymal transition (EMT), a developmental process by which epithelial cells reduce intercellular adhesions and acquire fibroblastoid properties, has important roles in the development of the invasive and metastatic potentials of cancer progression (6–8). To date, numerous clinicopathologic studies have shown positive correlations between the expressions of the transcription factors SNAI1 (snail homologue 1/SNAIL) and SNAI2 (snail homologue 2/Slug), which are key inducible factors of the EMT, and poor clinical outcomes in breast, ovary, colorectal, and lung cancer; squamous cell carcinoma; melanoma, and HCC (reviewed in ref. 6).

Generally, the activation of a wide variety of ligands including FGF (fibroblast growth factor), TGF- β -BMPs (bone morphogenetic protein), Wnt, EGF (epidermal growth factor), VEGF, and HGF (hepatocyte growth factor) and its receptor can upregulate the expression of EMT-regulating transcription factors, including SNAI1, SNAI2, ZEB1, ZEB2, and TWIST (6). Among them, HGF (also known as scattering factor) activates

Authors' Affiliations: Departments of ¹Genome Biology, ²Gastroenterology and ³Medical Oncology, Kinki University School of Medicine, Japan

Note: Supplementary material for this article is available at Molecular Cancer Therapeutics Online (<http://mct.aacrjournals.org>).

Corresponding Author: Kazuto Nishio, Department of Genome Biology, Kinki University School of Medicine, 377-2 Ohno-higashi, Osaka-Sayama, Osaka 589-8511, Japan. Phone: 81-72-366-0221 (ext 3150); Fax: 81-72-367-6369; E-mail: knishio@med.kindai.ac.jp

doi: 10.1158/1535-7163.MCT-10-0544

©2011 American Association for Cancer Research.

the Met signaling pathway, thereby increasing the invasive and metastatic potentials of the cells and allowing the survival of cancer cells in the bloodstream in the absence of anchorage (9). In addition, HGF is well known as a potent angiogenic cytokine, and Met signal activation can modify the microenvironment to facilitate cancer progression (9). Therefore, the HGF-Met signaling pathway is regarded as a promising therapeutic target, and many molecular targeted drugs are under clinical development (10). In HCC, the mRNA levels of HGF and Met receptor are markedly increased compared with those in normal liver (11). A high serum HGF concentration is associated with a poor prognosis for overall survival after hepatic resection, and the serum level of HGF represents the degree of the carcinogenic state in the livers of patients with C-viral chronic hepatitis and cirrhosis (12–14). Thus, we examined the effect of sorafenib on the HGF-Met-mediated EMT in HCC.

Materials and Methods

Reagents

Sorafenib was provided by Bayer HealthCare Pharmaceuticals Inc. U0126, wortmannin (Cell Signaling Technology), and human HGF (R&D Systems) were purchased from the indicated companies. The structures of compounds are shown in Supplementary Figure 1.

Cell culture

The human HCC cell lines HepG2 and Huh7 were maintained in Dulbecco's modified Eagle's (DMEM) medium (Sigma) supplemented with 10% FBS, penicillin, and streptomycin (Sigma) in a humidified atmosphere of 5% CO₂ at 37°C. The cell lines were obtained from the Japanese Collection of Research Bioresources and were grown in culture for less than 6 months.

Scratch assay

The method used for the scratches assay has been previously described (15). Briefly, the cells were plated onto 24-well plates and incubated in DMEM containing 10% FBS until they reached subconfluence. Scratches were introduced to the subconfluent cell monolayer, using a plastic pipette tip. The cells were then cultured with DMEM containing 10% FBS at 37°C. After 24 hours, the scratch area was photographed using a light microscope (IX71; Olympus). The wound distance between edge to edge were measured and averaged from 5 points per 1 wound area, using DP manager software (Olympus). The 2 wound areas were evaluated in an experiment and the experiment was done in triplicate.

Migration assay

The migration assays were done using the Boyden chamber methods and polycarbonate membranes with an 8- μ m pore size (Chemotaxicell), as previously described (15). The membranes were coated with fibronectin on the outer side and dried for 2 hours at room

temperature. The cells to be analyzed (2×10^4 cells/well) were then seeded onto the upper chambers with 200 μ L of migrating medium (DMEM containing 0.5% FBS), and the upper chambers were placed into the lower chambers of 24-well culture dishes containing 600 μ L of DMEM containing 10% FBS or with 10 ng/mL of HGF or with HGF and 10 μ mol/L of sorafenib. After incubation for 36 hours (HepG2) and 24 hours (Huh7), the media in the upper chambers were aspirated and the nonmigrated cells on the inner sides of the membranes were removed using a cotton swab. The cells that had migrated to the outer side of the membranes were fixed with 4% paraformaldehyde for 10 minutes, stained with 0.1% Giemsa stain solution for 15 minutes, and then counted using a light microscope. Migrated cells were averaged from 5 fields per 1 chamber and 3 chambers were used on 1 experiment. The experiment was done in triplicate.

Morphologic analysis

HepG2 and Huh7 cells (2×10^4 and 1×10^4 cells/well, respectively) were seeded in 6-well tissue culture dishes. After 24 hours of incubation, the cells were stimulated with 10 ng/mL of HGF or control PBS. When the inhibitors were used, the cells were exposed to each inhibitor for 3 hours before the addition of HGF. After 48 hours, the cells were analyzed using a light microscope. The experiment was done in triplicate.

Western blot analysis

The following antibodies were used in this study: phospho-Met (Y1349), Met, phospho-AKT (S473), AKT, phospho-p44/42 mitogen-activated protein kinase (MAPK), SNAI1/Snail, E-cadherin, N-cadherin, vimentin, β -actin antibody horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technology), and fibronectin (Santa Cruz Biotechnology). All the experiments were done at least in duplicate. The Western blot analysis was done as described previously (16). The data were quantified by automated densitometry using Multi-gauge Ver. 3.0 (Fujifilm). Densitometric data were normalized by β -actin in triplicate and the average was shown above the Western blot as a ratio of control sample.

Real-time reverse transcription PCR

The real-time reverse transcription PCR (RT-PCR) method has been previously described (17). Briefly, 1 μ g of total RNA from the cultured cells was converted to cDNA using a GeneAmp RNA-PCR kit (Applied Biosystems). Real-time RT-PCR amplification was done using a Thermal Cycler Dice (Takara) in accordance with the manufacturer's instructions under the following conditions: 95°C for 6 minutes, 40 cycles of 95°C for 15 seconds, and 60°C for 1 minute. Glyceraldehyde 3-phosphate dehydrogenase (GAPD) was used to normalize the expression levels in the subsequent quantitative analyses. To amplify the target genes, the following primers were purchased from TaKaRa: *CDH1*, forward 5'-TTA AAC




Figure 1. HGF stimulates the Met signaling pathway and induces morphologic changes in HCC. A, HGF stimulation (0, 0.1, 1, and 10 ng/mL) dose-dependently increased the phosphorylation of Met, MAPK, and AKT in the HCC cell lines HepG2 and Huh7. The results of a Western blot analysis are shown. β -Actin was used as a loading control. The serum-starved cells were stimulated with HGF for 60 minutes and then collected for analysis. B, time-course analysis of HGF stimulation. The HCC cells were stimulated with 10 ng/mL of HGF for 0, 1, 2, 4, 8, 12, and 24 hours. The results of a Western blot analysis are shown. C, HGF-mediated morphologic changes included cell scattering and the elongation of the cell shape that are characteristic of the EMT. The HepG2 and Huh7 cells were stimulated with or without 10 ng/mL of HGF for 48 hours and then photographed (magnification \times 200).

TCC TGG CCT CAA GCA ATC-3' and reverse 5'-TCC TAT CTT GGG CAA AGC AAC TG-3'; *CDH2*, forward 5'-CGA ATG GAT GAA AGA CCC ATC C-3' and reverse 5'-GGA GCC ACT GCC TTC ATA GTC AA-3'; *SNAIL*, forward 5'-TCT AGG CCC TGG CTG CTA CAA-3' and reverse 5'-ACA TCT GAG TGG GTC TGG AGG TG-3'; *SNAIL2*, forward 5'-ATG CAT ATT CGG ACC CAC ACA TTA C-3' and reverse 5'-AGA TTT GAC CTG TCT GCA AAT GCT C-3'; *VIM*, forward 5'-TGA GTA CCG GAG ACA GGT GCA G-3' and reverse 5'-TAG CAG CTT CAA CGG CAA AGT TC-3'; *FN1*, forward 5'-GGA GCA AAT GGC ACC GAG ATA-3' and reverse 5'-GAG CTG CAC ATG TCT TGG GAA C-3'; and *GAPD*, forward 5'-GCA CCG TCA AGG CTG AGA AC-3' and reverse 5'-ATG GTG GTG AAG ACG CCA GT-3'.

Small interfering RNA transfection

Three different sequences of small interfering RNA (siRNA) targeting human *SNAIL* (Hs_SNAI1_9785, 9786, and 9787) and those of 2 scramble control siRNAs were purchased from Sigma Aldrich Japan. The transfection methods have been previously described (17).

Statistical analysis

The statistical analyses were done using Microsoft Excel (Microsoft) both to calculate the SD and to test

for statistically significant differences between the samples using a Student *t* test. A value $P < 0.05$ was considered statistically significant.

Results

To examine the activity of HGF-Met signaling in HCC cells, we examined the expressions of phospho-Met, Met, phospho-AKT, AKT, phospho-MAPK, and MAPK in the HepG2 and Huh7 cell lines, using Western blotting. The phosphorylation levels of Met, AKT, and MAPK were dose-dependently increased by HGF stimulation (Fig. 1A). A time-course analysis showed that the phosphorylation levels of Met, AKT, and MAPK peaked at 1 to 2 hours after HGF stimulation and gradually recovered to the baseline values at 4 hours later (Fig. 1B). These results indicated that Met signaling is actually capable of being activated in response to HGF in HCC cells.

From a morphologic aspect, the EMT is characterized by an increase in cell scattering and an elongation of the cell shape (18). To evaluate whether HGF mediates the morphologic change that is characteristic of the EMT in HCC cells, cellular morphology was examined after HGF stimulation. HGF clearly mediated both cell scattering and the elongation of the cell shape in HepG2 and Huh7 cell lines (Fig. 1C). These data indicate that HGF mediates




Figure 2. HGF upregulates SNAI1 expression and induces cadherin switching in HCC. A, changes in the mRNA expressions of the EMT-related genes *SNAI1/Snai1*, *SNAI2/Slug*, *E-cadherin/CDH1*, *N-cadherin/CDH2*, and *fibronectin/FN1* were determined using real-time RT-PCR. The HepG2 and Huh7 cells were stimulated with or without 10 ng/mL of HGF for 2 hours (*SNAI1* and *SNAI2*) or 48 hours (*E-cad*, *N-cad*, and *FN1*). Rel mRNA, normalized mRNA expression levels (target genes/GAPD $\times 10^4$); *E-cad*, E-cadherin; *N-cad*, N-cadherin. B, the HGF-mediated protein expression changes in *SNAI1*, E-cadherin, N-cadherin, fibronectin, and vimentin were determined using a Western blot analysis. The HepG2 and Huh7 cells were stimulated with HGF at the indicated dose (0, 0.1, 1, or 10 ng/mL) and collected for analysis after 4-hour stimulation for *SNAI1* and 72 hours for the others. C, the cells were stimulated with 10 ng/mL of HGF for the indicated time course (0, 1, 2, 4, 8, 12, or 24 hours) and used for analysis. β -Actin was used as a loading control. D, Western blot analysis of E-cadherin and N-cadherin. The cells were stimulated with 10 ng/mL of HGF for 0, 48, and 96 hours and then analyzed.

the morphologic changes that are compatible with the induction of the EMT in HCC cell lines.

Because *SNAI1* and *SNAI2* are considered to be master regulators of the EMT, changes in the mRNA expression levels of EMT-related genes in response to HGF stimulation were evaluated using real-time RT-PCR (Fig. 2A). HGF stimulation upregulated *SNAI1* mRNA expression by more than 2-fold, whereas the baseline expression of *SNAI2* was very low compared with that of *SNAI1* and did not respond to HGF in either of the HCC cell lines that were examined. Cadherin switching, which is characterized by the downregulation of E-cadherin and the upregulation of N-cadherin, is known as one of the most pivotal cellular events in the EMT (19). Cadherin switching was clearly observed on the basis of mRNA levels

after HGF stimulation. The mesenchymal marker fibronectin was also upregulated (Fig. 2A).

Consistent with the mRNA changes, HGF stimulation dose-dependently upregulated the protein expression of *SNAI1*, N-cadherin, fibronectin, and vimentin and downregulated the expression of E-cadherin in both cell lines (Fig. 2B). Vimentin expression of HepG2 was not detected (baseline vimentin mRNA was also extremely low; data not shown). A time-course analysis showed that HGF upregulated the *SNAI1* expression at 2 hours after stimulation and that the expression level recovered to the baseline value at 24 hours thereafter (Fig. 2C). Cadherin switching after HGF stimulation was observed at 8 hours later in HepG2 cells and 48 hours later in Huh7 cells (Fig. 2C and D). Generally, upregulation of *SNAI1* is




Figure 3. SNAI1 is required to induce the HGF-mediated EMT in HCC cells. A, knockdown of HGF-mediated SNAI1 expression using siRNA. Three sequences of SNAI1-siRNA (1, 2, and 3) were used. The HepG2 and Huh7 cells were treated with or without 50 nmol/L of each siRNA for 48 hours and then were stimulated with 10 ng/mL of HGF. SNAI1-siRNA #2 was effective and was used in subsequent experiments. B, SNAI1 knockdown canceled the HGF-mediated morphologic changes. The HepG2 and Huh7 cells were treated with 50 nmol/L of siRNA for 48 hours and were then stimulated with 10 ng/mL of HGF in all 4 panels. C, SNAI1 suppression by siRNA strongly canceled the HGF-mediated downregulation of E-cadherin and the upregulation of N-cadherin in both HepG2 and Huh7 cells. The cells were treated with 50 nmol/L of siRNA for 48 hours and were analyzed using a Western blot analysis. Densitometric data are shown above the Western blot. D, the siRNA knockdown of SNAI1 inhibited the HGF-mediated cellular migration. The siRNA-transfected HepG2 and Huh7 cells were evaluated using migration assay. The migration assays were conducted using the Boyden chamber methods as described in Materials and Methods. *, $P < 0.05$ (Cont-si vs. SNAI1-si with HGF); Cont-si, control-siRNA; SNAI1-si, SNAI1-targeting siRNA.

observed within few hours, but cadherin switching occurs around 24 hours later after stimulation (20, 21), consistent with our result. These results indicate that HGF mediates the induction of SNAI1, cadherin switching, and the EMT in HCC cells.

Besides SNAI1 and SNAI2, other transcription factors of several genes also have the potential to repress E-cadherin and to induce the EMT; these factors include ZEB1/TCF8, ZEB2/SMAD interacting protein 1, TWIST, E47/TCF3, and TCF4/E2-2 (6). Therefore, we examined whether SNAI1, among several EMT-inducible genes, has a central role in the HGF-mediated EMT in HCC cells. Three sequences of SNAI1-siRNA (1, 2, and 3) were used. A Western blot showed that both sequences 2 and 3 of SNAI1-siRNA completely suppressed the HGF-mediated upregulation of SNAI1 in the HepG2 and Huh7 cells (Fig. 3A); thus, the #2 SNAI1-siRNA was used in the following experiments: The siRNA knockdown of SNAI1 canceled the morphologic changes observed in HepG2 cells undergoing HGF-mediated EMT, whereas the control-siRNA did not (Fig. 3B). Similar results were

obtained in Huh7 cells, indicating that SNAI1 is required for the morphologic changes observed in HGF-mediated EMT. Similarly, the siRNA knockdown of SNAI1 strongly canceled the HGF-mediated downregulation of E-cadherin and the upregulation of N-cadherin in both HepG2 and Huh7 cells (Fig. 3C). Those of mRNA expression changes were relatively correlated with the results of Western blot, except for N-cadherin in Huh7 cells (Supplementary Fig. 2A). Regarding the cellular migration, the siRNA knockdown of SNAI1 inhibited the HGF-mediated cellular migration (Fig. 3D). Collectively, these results indicate that SNAI1 is required to induce the HGF-mediated EMT in HCC cells.

In general, SNAI1 expression is regulated by ligand-receptor signal transduction through a downstream signal pathway that includes the Smad, MAPK, AKT, and GSK3 pathways (6, 22, 23). Sorafenib has been shown to inhibit RAF-MAPK signaling in HCC cells (24). Accordingly, we hypothesized that sorafenib might downregulate SNAI1 expression by inhibiting RAF-MAPK signaling, which is a unique activity of sorafenib. As




Figure 4. Sorafenib downregulates SNAI1 expression in HCC. A, as expected, sorafenib and the MEK inhibitor U0126 inhibited the HGF-mediated phosphorylation of MAPK, but the PI3K inhibitor wortmannin did not. Of note, SNAI1 expression was markedly downregulated by sorafenib and U0126. The HepG2 and Huh7 cells were exposed to 10 $\mu\text{mol/L}$ of sorafenib or wortmannin or U0126 for 3 hours and were then stimulated with 10 ng/mL of HGF for 60 minutes. Wort, wortmannin. B, the HGF-mediated morphologic changes were canceled by sorafenib and U0126 but not by wortmannin in the HCC cells. The cells were exposed to sorafenib or wortmannin or U0126 for 48 hours with or without HGF (10 ng/mL) and then photographed. C, HGF-mediated downregulation of E-cadherin was canceled by sorafenib. The cells were stimulated with HGF (10 ng/mL) and treated with sorafenib at indicated concentration for 48 hours. D, HGF-mediated cadherin switching and upregulation of fibronectin and vimentin were canceled by sorafenib in the HCC cell lines. The cells were cultured with or without 2 $\mu\text{mol/L}$ of sorafenib for 72 hours, with or without HGF (10 ng/mL), and then were analyzed using Western blot analysis. Densitometric data are shown above the Western blot.

expected, sorafenib and the MEK inhibitor U0126 (10 $\mu\text{mol/L}$) markedly inhibited the HGF-induced phosphorylation of MAPK, but the PI3K inhibitor wortmannin (10 $\mu\text{mol/L}$) did not. In contrast, only wortmannin inhibited the phosphorylation of AKT (Fig. 4A). Notably, SNAI1 expression was strongly downregulated by sorafenib and U0126 but not by wortmannin (Fig. 4A). These results showed that sorafenib downregulated SNAI1 expression via MAPK signaling. Meanwhile, we examined the HGF- and sorafenib-mediated expression changes of *SNAI2*, *ZEB1*, *ZEB2*, and *TWIST* using real-time RT-PCR and Western blot (Supplementary Fig. 3). Baseline and expression changes of *SNAI2* and *TWIST* were very low compared with *SNAI1*, and the expression changes of *ZEB1* and *ZEB2* seemed not to be significant. Collectively, we considered that *SNAI2*, *TWIST*, *ZEB1*, and *ZEB2* are not likely to be involved in the effect of HGF and sorafenib on EMT in this cell lines. Then, we examined the activity of sorafenib on HGF-mediated morpho-

logic changes in HCC cells. HGF stimulation mediated the cell scattering and spindle-shaped changes, and these effects were clearly canceled by sorafenib and U0126, but not by wortmannin, in both HepG2 and Huh7 cells (Fig. 4B). These results were consistent with the results of Western blotting. To show whether sorafenib cancels the effect of HGF-mediated downregulation of E-cadherin, we examined the Western blot in dose-response analysis. Downregulation of E-cadherin was clearly canceled by sorafenib in a dose-dependent manner (Fig. 4C). Time-course analysis showed that HGF-mediated downregulation of E-cadherin was also canceled by sorafenib (Supplementary Fig. 4). HGF stimulation downregulated E-cadherin expression and upregulated N-cadherin, vimentin, and fibronectin in HCC cells; however, these effects were canceled by sorafenib in both HCC cell lines (Fig. 4D and Supplementary Fig. 2B). The mRNA data of N-cadherin in Huh7 cells were not correlated with protein level. These results show that sorafenib inhibits the

RAF-MAPK pathway, thereby downregulating SNAI1 and inhibiting the EMT in HCC.

Because sorafenib inhibits the HGF-mediated EMT in HCC cells, we next examined whether the inhibitory effect of sorafenib on the EMT leads to an inhibition of cellular migration in HCC cells. A scratch assay revealed that HGF stimulation increased cellular migration by about 2-fold in both HCC cell lines; however, sorafenib significantly inhibited this effect to the baseline levels (Fig. 5A). Similarly, a migration assay using the Boyden chamber method revealed that sorafenib canceled HGF-mediated cellular migration in both cell lines (Fig. 5B). These results suggest that sorafenib actually inhibits the cellular migrating phenotype of the EMT in HCC cells. The combination of migration data with siRNA and sorafenib (Fig. 3D and Fig. 5B) suggests that inhibitory effects of sorafenib on migration may be mediated by Snail downregulation in some tumors (e.g., Huh7) but not in others (e.g., HepG2). It is assumed that the inhibitory activity of sorafenib on the cellular migrating phenotype is due to its inhibitory effect of Raf-MAPK signaling pathway (Fig. 4A and B). Regarding HGF-dependent PI3K-AKT signaling pathway, wortmannin weakly inhibited the wound closure in Huh7 cells and to the same extent by sorafenib in HepG2 cells (Supplementary Fig. 5). In contrast, wortmannin has no effect on Snail levels or on HCC morphology changes (Fig. 4A and B). Collectively, we speculate that activation of HGF-dependent PI3K-AKT pathway may not be involved in SNAI1 induction or morphologic change but at least partially involved in cell migration independent of Raf-MAPK-SNAI1 signaling.

Taken together, these results indicate that sorafenib inhibits the HGF-mediated EMT, which is characterized by cadherin switching, morphologic changes, and an increase in the cellular migrating phenotype, by inhibiting Raf-MAPK signaling, resulting in the downregulation of SNAI1 in HCC cells (Fig. 6).

Discussion

Recent accumulating evidence has shown that the EMT is involved in drug sensitivity to several anticancer agents (25). Within this topic, the most intensively investigated drugs have been endothelial growth factor receptor (EGFR)-targeting drugs for the treatment of lung cancer. A clinical trial has revealed that lung cancer cells with strong E-cadherin expression exhibit a significantly longer time to progression after EGFR-TKI (tyrosine kinase inhibitor) treatment (26). Other studies on EGFR-targeting drugs have shown that mesenchymal type lung cancer cells exhibit an EMT-dependent acquisition of PDGFR, FGF receptor, and TGF- β receptor signaling pathways (27), and integrin-linked kinase is a novel target for overcoming HCC resistance to EGFR inhibition (28). Regarding sensitivity to gemcitabine, mesenchymal type cancer cells are reportedly associated with gemcitabine resistance in pancreatic cancer cells (29). The mechanism of resistance to gemcitabine has been shown




Figure 5. Sorafenib inhibits HGF-mediated cellular migration in HCC cells. A, a scratch assay revealed that HGF stimulation increased the cellular migration by about 2-fold, but sorafenib almost completely canceled the effect. The subconfluent HepG2 and Huh7 cells were scratched with a plastic pipette tip and incubated under the indicated conditions (control, 10 ng/mL of HGF; and HGF, 10 μ mol/L of sorafenib). The scratch area was photographed and measured. The experiment was done in triplicate. *, sorafenib (-) versus (+), $P < 0.05$. B, migration assay using the Boyden chamber method revealed that sorafenib almost completely canceled the HGF-mediated cellular migration in both HCC cell lines. The cells were incubated under the indicated conditions: control, 10 ng/mL of HGF; and HGF, 10 μ mol/L of sorafenib. *, sorafenib (-) versus (+), $P < 0.05$. Sora, sorafenib.

to involve the activation of Notch signaling, which is mechanistically linked with the mesenchymal chemoresistance phenotype of pancreatic cancer cells (30). Thus, baseline cellular characteristics based on the EMT phenotype might be useful not only as prognostic biomarkers for a malignant phenotype but also as predictive markers




Figure 6. Diagram of the proposed mechanism by which sorafenib inhibits the EMT. Sorafenib inhibits the HGF-mediated EMT, which is characterized by morphologic changes, cadherin switching, and an increase in the cellular migrating phenotype. The anti-EMT effect of sorafenib occurs through the downregulation of SNAI1 by the inhibition of MAPK phosphorylation in HCC cells. Wort, wortmannin; N-cad, N-cadherin; E-cad, E-cadherin.

of sensitivity to anticancer agents. In this study, we focused on the signaling pathway responsible for inducing the EMT and showed that the multitarget TKI sorafenib downregulates SNAI1 by inhibiting Raf-MAPK signaling, thereby inhibiting the HGF-mediated EMT in HCC cells. Our findings may provide a novel insight into the actions of TKIs and their anti-EMT effects.

The mechanisms underlying the SNAI1-induced metastatic and aggressive phenotypes of cancer cells have recently been intensively investigated in both basic and clinical research studies. A novel aspect of the activity of SNAI1 is its involvement in immunosuppression. The

SNAI1-induced EMT mediates regulatory T cells and impairs dendritic cells, accelerating cancer metastasis not only by enhancing invasion but also by inducing immunosuppression (31). A complex of histone deacetylase (HDAC) and SNAI1 plays an essential role in silencing E-cadherin (32), suggesting that the use of HDAC inhibitors to inhibit SNAI1 function might represent a promising therapeutic approach. On the other hand, large-scale clinical data on SNAI1 expression and the prognosis of patients with HCC were recently reported (33) and the overexpression of SNAI2 and/or TWIST was correlated with a worse prognosis. In contrast, no such significant differences were observed in samples that overexpressed SNAI2. The coexpression of Snail and TWIST was correlated with the worst prognosis for HCC (33). This evidence suggests that SNAI1 might be a useful therapeutic target for oncology. Our findings showed that sorafenib completely canceled the HGF-mediated SNAI1 induction in HepG2 and Huh7 cells. This activity of sorafenib, in addition to sorafenib's anti-angiogenic effects, might contribute to a clinical benefit against metastatic and aggressive phenotypes in patients with HCC.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Tomoko Kitayama and the staff of the Life Science Research Institute for their technical assistance.

Grant Support

This work was supported in part by the Third-Term Comprehensive 10-Year Strategy for Cancer Control and a Grant-in-Aid for Cancer Research (H20-20-9) from the Ministry of Health and Labor Scientific Research Grants.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received June 9, 2010; revised October 25, 2010; accepted October 25, 2010; published online January 10, 2011

References

- Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. *CA Cancer J Clin* 2005;55:10–30.
- Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. *Br J Surg* 1996;83:1219–22.
- Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. *Cancer Res* 2004;64:7099–109.
- Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008;359:378–90.
- Cheng AL, Kang YK, Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009;10:25–34.
- Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? *Nat Rev Cancer* 2007;7:415–28.
- Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. *J Cell Physiol* 2007;213:374–83.
- Tsuji T, Ibaragi S, Hu GF. Epithelial-mesenchymal transition and cell cooperativity in metastasis. *Cancer Res* 2009;69:7135–9.
- Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. *Cancer Metastasis Rev* 2008;27:85–94.
- Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. *Clin Cancer Res* 2009;15:2207–14.
- Yang H, Magilnick N, Nouredin M, Mato JM, Lu SC. Effect of hepatocyte growth factor on methionine adenosyltransferase genes